On Friday, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s shares declined -0.78% to $184.45.
Alexion Pharmaceuticals, Inc. (ALXN) declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending marketing authorization of Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa). The projected indication for Strensiq is for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. The projected indication for Kanuma is for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency (LAL-d). Based on the CHMP’s positive recommendations, final decisions from the European Commission are predictable in the third quarter of 2015, after which the Company will start the country-by-country reimbursement processes. Presently, there are no therapies approved for the treatment of HPP or LAL-d.
HPP is a genetic, progressive, ultra-rare metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. It is characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, in addition to systemic complications such as profound muscle weakness, seizures, pain and respiratory failure leading to premature death in infants.1-5
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
Intuit Inc. (NASDAQ:INTU)’s shares dropped -0.35% to $103.24.
Intuit Inc. (INTU) QuickBooks Connect is returning to San Jose, Calif., with notable names joining the main stage lineup, counting The Honest Company’s Jessica Alba, founder and chief creative officer, and Brian Lee, co-founder and chief executive officer, in addition to Sekou Andrews, entrepreneur and poetic motivational speaker. Intuit QuickBooks will present these and other speakers with the aim of inspiring attendees and sharing lessons for small business success. Attendees can register at www.QuickBooksConnect.com.
Taking place Nov. 2-4, QuickBooks Connect will unite thousands of entrepreneurs, small businesses, accountants and developers under one roof to get connected, educated and inspired via hands-on breakout sessions, engaging main stage presentations and unique networking opportunities. Building on the success of last year’s event, QuickBooks Connect will feature a dynamic agenda and experience designed to assist attendees’ businesses grow and succeed. Alba, Lee, Andrews and others yet to be declared will speak on Nov. 3 during the main stage event.
Intuit Inc. provides business and financial administration solutions for small businesses, consumers, and accounting professionals in the United States, Canada, the United Kingdom, Australia, India, and Singapore. The company’s Small Business segment provides QuickBooks financial and business administration online services and desktop software; QuickBooks technical support services; financial supplies; and small business payroll products and services.
At the end of Friday’s trade, Infinera Corp. (NASDAQ:INFN)‘s shares dipped -2.07% to $21.24.
Infinera, provider of Intelligent Transport Networks, declared the expansion of the Cloud Xpress family of metro Cloud platforms. This release adds a new Cloud Xpress platform with 100 gigabit Ethernet (GbE) client services in the same compact form factor together with improved functionality. The Cloud Xpress family is designed specifically to address the needs of Cloud service providers, Internet content providers, Internet Exchange service providers, large enterprises and other large-scale datacenter operators.
The Cloud Xpress family, which first started shipping in December 2014, leverages the oPIC-500 optical engine, Infinera’s unique metro-optimized photonic integrated circuit, to deliver DWDM datacenter interconnect services up to 500 gigabits per second (Gb/s) in a compact two rack unit chassis. The new Cloud Xpress with 100 GbE extends the hyper-scale density, simplified operations and low power of the existing Cloud Xpress family that operators can use to easily deploy and scale their networks. With the addition of the new platform, the Cloud Xpress family now supports 10 GbE, 40 GbE and 100 GbE client-side interfaces to match customer specific requirements.
Together with the introduction of the new Cloud Xpress with 100 GbE, Infinera declared important enhancements to the Cloud Xpress family counting MACsec encryption for improved security, NETCONF & YANG support for Software Defined Networking (SDN) and ease of use, and LLDP discovery protocols enabling datacenter automation.
Infinera Corporation provides optical transport networking equipment, software, and services for telecommunications service providers, Internet content providers, cable operators, wholesale and enterprise carriers, research and education institutions, and government entities worldwide.
Regulus Therapeutics Inc (NASDAQ:RGLS), ended its Friday’s trading session with 0.49% gain, and closed at $10.27.
Regulus Therapeutics Inc (RGLS) amended the compensation terms of its Employment Agreement with Paul Grint, M.D., the Company’s President and Chief Executive Officer (the “Amended Terms”). Under the Amended Terms, Dr. Grint is entitled to receive an annual base salary of $500,000 effective June 1, 2015, the date of his appointment to President and Chief Executive Officer. In addition, Dr. Grint is eligible to receive an annual performance bonus based on a target amount of 50% of his annual base salary, which raised target bonus is also effective as of June 1, 2015. In addition, on June 25, 2015, Dr. Grint was granted a stock option to purchase 500,000 shares of the Company’s common stock with an exercise price of $10.22. Twenty-five percent of the option will vest on the first anniversary of the date of grant and the remainder will vest in equal monthly installments over the following thirty-six months such that the option will be fully vested four years after the date of grant, subject to Dr. Grint’s Continuous Service to the Company, as that term is defined in the Company’s 2012 Equity Incentive Plan. Dr. Grint’s base salary and target bonus percentage are subject to modification from time to time in the discretion of the Board of Directors or any authorized committee thereof.
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
